Advertisement
YOU ARE HERE: LAT HomeCollectionsRhone Poulenc Rorer Inc
IN THE NEWS

Rhone Poulenc Rorer Inc

FEATURED ARTICLES
BUSINESS
November 15, 1994 | From Times Staff and Wire Reports
French Drug Company Announces Biotech Consortium: Rhone-Poulenc Rorer Inc. said 14 companies and research groups will explore gene and cell therapy treatments for cancer, heart and circulatory diseases, AIDS, Alzheimer's and other afflictions. Rhone plans to spend $100 million in each of the next two years, or about 15% of its total research and development budget, on the project, which involves small biotechnology companies, U.S.
ARTICLES BY DATE
NEWS
December 16, 1997 | From Associated Press
The government said Monday that a new blood thinner could leave some surgical patients paralyzed. The Food and Drug Administration has received more than 30 reports of patients who suffered bleeding inside the spinal column after taking a blood thinner called Lovenox, made by Rhone-Poulenc Rorer, and receiving surgical anesthesia by spinal injection. Some patients suffered temporary neurological damage, such as leg weakness, difficulty walking or difficulty emptying their bladders.
Advertisement
BUSINESS
June 4, 1993 | From Associated Press
Pharmaceutical maker Rhone-Poulenc Rorer Inc. will invest $113 million in a small California biotech company specializing in sophisticated cell and gene therapies, the companies said Thursday. The deal, which gives Rhone-Poulenc Rorer a 37% stake in Santa Clara-based Applied Immune Sciences Inc. as well as the option to acquire another 23%, is the latest example of a big drug company buying access to cutting-edge science. In over-the-counter trading, AIS jumped $3.87 1/2 a share to $22.87 1/2.
BUSINESS
October 12, 1995 | Times Staff and Wire Reports
Fisons Agrees to Takeover by Rhone-Poulenc Rorer: Fisons, which had rejected previous Rhone-Poulenc Rorer offers, said it agreed to the French-U.S. company's latest bid, of $2.9 billion, after talks with a potential "white knight" collapsed. Fisons Chief Executive Stuart Wallis gave no specific details on which firm had considered striking a deal. Some analysts said the announcement of an aborted rescue deal may have been a face-saving exercise for Fisons.
BUSINESS
October 6, 1995 | Times Staff and Wire Reports
Rorer Raises Fisons Bid: The French-U.S. drug manufacturer Rhone-Poulenc Rorer Inc. raised its hostile bid for Fisons to $2.9 billion, but the British maker of asthma treatments and other medicines swiftly rejected the new offer. "This is certainly a full price for Fisons," Rorer Chairman Robert Cawthorn said. He said shareholders now have to choose between "this very handsome price for this company" or stick with Fisons as an independent entity.
BUSINESS
September 24, 1991
Baxter Healthcare Corp. said it asked a federal court to dismiss a patent-infringement claim against one of its drugs that helps stop bleeding in hemophiliacs. The drug is manufactured by Baxter's Hyland division in Glendale. The U.S. patent in question is held by The Scripps Research Institute and is licensed to a French pharmaceutical company, Rhone-Poulenc Rorer Inc., which filed a motion Sept. 12 to stop Baxter Healthcare from selling its version of the drug.
BUSINESS
October 6, 1995 | Times Staff and Wire Reports
Rorer Raises Fisons Bid: The French-U.S. drug manufacturer Rhone-Poulenc Rorer Inc. raised its hostile bid for Fisons to $2.9 billion, but the British maker of asthma treatments and other medicines swiftly rejected the new offer. "This is certainly a full price for Fisons," Rorer Chairman Robert Cawthorn said. He said shareholders now have to choose between "this very handsome price for this company" or stick with Fisons as an independent entity.
BUSINESS
August 19, 1995 | From Reuters
Rhone-Poulenc Rorer Inc., the big French-owned drug producer, offered $2.61 billion on Friday to buy Fisons, but the troubled British drug manufacturer rejected the takeover bid as too low. The offer is the latest in an industry that has seen a number of big mergers this year, including a $14.3-billion deal in March that formed Glaxo-Wellcome, now the world's biggest drug manufacturer.
BUSINESS
March 7, 1995 | Times Staff and Wire Reports
FDA Approves Drugs for Angina Treatment: Rhone-Poulenc Rorer Inc. said the Food and Drug Administration has approved its diltiazem hydrochloride drug to treat chronic stable angina. Ivax Corp. said its generic version of diltiazem hydrochloride has also been given FDA approval, also for angina. Diltiazem hydrochloride is part of a group of drugs known as calcium channel blockers, which restrict the movement of calcium into the cells of heart and blood vessels.
Los Angeles Times Articles
|